Skip to main content
SpringerLink
Log in

Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: The MILRISPASM Controlled Before–After Study

  • Original work
  • Published:
Neurocritical Care Aims and scope Submit manuscript

A Letters to the editor to this article was published on 23 November 2021

A Letters to the editor to this article was published on 03 November 2021

A Response to this article was published on 01 November 2021

Abstract

Background

Intravenous (IV) milrinone, in combination with induced hypertension, has been proposed as a treatment option for cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). However, data on its safety and efficacy are scarce.

Methods

This was a controlled observational study conducted in an academic hospital with prospectively and retrospectively collected data. Consecutive patients with cerebral vasospasm following aSAH and treated with both IV milrinone (0.5 µg/kg/min−1, as part of a strict protocol) and induced hypertension were compared with a historical control group receiving hypertension alone. Multivariable analyses aimed at minimizing potential biases. We assessed (1) 6-month functional disability (defined as a score between 2 and 6 on the modified Rankin Scale) and vasospasm-related brain infarction, (2) the rate of first-line or rescue endovascular angioplasty for vasospasm, and (3) immediate tolerance to IV milrinone.

Results

Ninety-four patients were included (41 and 53 in the IV milrinone and the control group, respectively). IV milrinone infusion was independently associated with a lower likelihood of 6-month functional disability (adjusted odds ratio [aOR] = 0.28, 95% confidence interval [CI] = 0.10–0.77]) and vasospasm-related brain infarction (aOR = 0.19, 95% CI 0.04–0.94). Endovascular angioplasty was less frequent in the IV milrinone group (6 [15%] vs. 28 [53%] patients, p = 0.0001, aOR = 0.12, 95% CI 0.04–0.38). IV milrinone (median duration of infusion, 5 [2–8] days) was prematurely discontinued owing to poor tolerance in 12 patients, mostly (n = 10) for “non/hardly-attained induced hypertension” (mean arterial blood pressure < 100 mmHg despite 1.5 µg/kg/min−1 of norepinephrine). However, this event was similarly observed in IV milrinone and control patients (n = 10 [24%] vs. n = 11 [21%], respectively, p = 0.68). IV milrinone was associated with a higher incidence of polyuria (IV milrinone patients had creatinine clearance of 191 [153–238] ml/min−1) and hyponatremia or hypokalemia, whereas arrhythmia, myocardial ischemia, and thrombocytopenia were infrequent.

Conclusions

Despite its premature discontinuation in 29% of patients as a result of its poor tolerance, IV milrinone was associated with a lower rate of endovascular angioplasty and a positive impact on long-term neurological and radiological outcomes. These preliminary findings encourage the conduction of confirmatory randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. de Oliveira Manoel AL, Goffi A, Marotta TR, Schweizer TA, Abrahamson S, Macdonald RL. The critical care management of poor-grade subarachnoid haemorrhage. Crit Care Lond Engl. 2016;20:21.

    Article  Google Scholar 

  2. Diringer MN, Bleck TP, Claude-Hemphill J, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211–40.

    Article  Google Scholar 

  3. Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012;43(6):1711–37.

    Article  Google Scholar 

  4. Linskey ME, Horton JA, Rao GR, Yonas H. Fatal rupture of the intracranial carotid artery during transluminal angioplasty for vasospasm induced by subarachnoid hemorrhage Case report. J Neurosurg. 1991;74(6):985–90.

    Article  CAS  Google Scholar 

  5. Dawkins AA, Evans AL, Wattam J, et al. Complications of cerebral angiography: a prospective analysis of 2,924 consecutive procedures. Neuroradiology. 2007;49(9):753–9.

    Article  CAS  Google Scholar 

  6. Derham C, Davies JF, Shahbazi R, Homer-Vanniasinkam S. Iatrogenic limb ischemia caused by angiography closure devices. Vasc Endovasc Surg. 2006;40(6):492–4.

    Article  Google Scholar 

  7. Kelkar PS, Fleming JB, Walters BC, Harrigan MR. Infection risk in neurointervention and cerebral angiography. Neurosurgery. 2013;72(3):327–31.

    Article  Google Scholar 

  8. Sakata H, Endo H, Fujimura M, Niizuma K, Tominaga T. Symptomatic cerebral hyperperfusion after cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage. World Neurosurg. 2020;137:379–83.

    Article  Google Scholar 

  9. Bercault N, Wolf M, Runge I, Fleury J-C, Boulain T. Intrahospital transport of critically ill ventilated patients: a risk factor for ventilator-associated pneumonia–a matched cohort study. Crit Care Med. 2005;33(11):2471–8.

    Article  Google Scholar 

  10. Küchler J, Tronnier F, Smith E, Gliemroth J, Tronnier VM, Ditz C. The impact of intrahospital transports on brain tissue metabolism in patients with acute brain injury. Neurocrit Care. 2019;30(1):216–23.

    Article  Google Scholar 

  11. Martin M, Cook F, Lobo D, et al. Secondary insults and adverse events during intrahospital transport of severe traumatic brain-injured patients. Neurocrit Care. 2017;26(1):87–95.

    Article  Google Scholar 

  12. Romero CM, Morales D, Reccius A, et al. Milrinone as a rescue therapy for symptomatic refractory cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;11(2):165–71.

    Article  CAS  Google Scholar 

  13. Schmidt U, Bittner E, Pivi S, Marota JJ. Hemodynamic management and outcome of patients treated for cerebral vasospasm with intraarterial nicardipine and/or milrinone. Anesth Analg. 2010;110(3):895–902.

    Article  CAS  Google Scholar 

  14. Lannes M, Zeiler F, Guichon C, Teitelbaum J. The use of milrinone in patients with delayed cerebral ischemia following subarachnoid hemorrhage: a systematic review. Can J Neurol Sci. 2016;44(2):152–60.

    Article  Google Scholar 

  15. Fraticelli AT, Cholley BP, Losser M-R, Saint Maurice J-P, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(3):893–8.

    Article  Google Scholar 

  16. Lannes M, Teitelbaum J, del Pilar CM, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16(3):354–62.

    Article  Google Scholar 

  17. Velly LJ, Bilotta F, Fabregas N, Soehle M, Bruder NJ, Nathanson MH. Anaesthetic and ICU management of aneurysmal subarachnoid haemorrhage: a survey of European practice. Eur J Anaesthesiol. 2015;32(3):168–76.

    CAS  PubMed  Google Scholar 

  18. Lakhal K, Rodie-Talbere P-A, Alexandre P-L, Testard N, Rozec B, Daumas-Duport B. Continuous intravenous milrinone for severe reversible cerebral vasoconstriction syndrome (a case report). J Neurol Sci. 2019;397:55–7.

    Article  Google Scholar 

  19. Morbitzer KA, Jordan JD, Dehne KA, Durr EA, Olm-Shipman CM, Rhoney DH. Enhanced renal clearance in patients with hemorrhagic stroke. Crit Care Med. 2019;47(6):800–8.

    Article  CAS  Google Scholar 

  20. Rumalla K, Lin M, Ding L, et al. Risk factors for cerebral vasospasm in aneurysmal subarachnoid hemorrhage: a population-based study of 8346 patients. World Neurosurg. 2021;145:e233–41.

    Article  Google Scholar 

  21. Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008;118(16):1619–25.

    Article  CAS  Google Scholar 

  22. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–89.

    Article  Google Scholar 

  23. Langfitt TW. Increased intracranial pressure. Clin Neurosurg. 1969;16:436–71.

    Article  CAS  Google Scholar 

  24. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044–54.

    Article  CAS  Google Scholar 

  25. Lakhal K, Robert-Edan V, Fresco M, et al. Transcranial Doppler in the diagnosis of cerebral vasospasm: a call for a dynamic approach. Crit Care Med. 2019;47(2):e164–5.

    Article  Google Scholar 

  26. Abulhasan YB, Ortiz Jimenez J, Teitelbaum J, Simoneau G, Angle MR. Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia. J Neurosurg. 2020;1:1–12.

    Google Scholar 

  27. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–83.

    Article  CAS  Google Scholar 

  28. Crespy T, Heintzelmann M, Chiron C, et al. Which protocol for milrinone to treat cerebral vasospasm associated with subarachnoid hemorrhage? J Neurosurg Anesthesiol. 2019;31(3):323–9.

    Article  Google Scholar 

  29. Ghanem MA, Shabana AM. Effects of Milrinone continuous intravenous infusion on global cerebral oxygenation and cerebral vasospasm after cerebral aneurysm surgical clipping. Egypt J Anaesth. 2014;30(1):73–82.

    Article  Google Scholar 

  30. Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. Neurosurgery. 2001;48(4):723–8.

    CAS  PubMed  Google Scholar 

  31. Santos-Teles AG, Ramalho C, Ramos JGR, et al. Efficacy and safety of milrinone in the treatment of cerebral vasospasm after subarachnoid hemorrhage: a systematic review. Rev Bras Ter Intensiva. 2020;32(4):592–602.

    Article  Google Scholar 

  32. Gathier CS, van den Bergh WM, van der Jagt M, et al. Induced hypertension for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a randomized clinical trial. Stroke. 2018;49(1):76–83.

    Article  Google Scholar 

  33. Cinotti R, Putegnat J-B, Lakhal K, et al. Evolution of neurological recovery during the first year after subarachnoid haemorrhage in a French university centre. Anaesth Crit Care Pain Med. 2019;38(3):251–7.

    Article  Google Scholar 

  34. University Hospital, Angers. Milrinone infusion for VAsospam treatment in subarachnoid hemoRrhage. clinicaltrials.gov; 2020. https://clinicaltrials.gov/ct2/show/NCT04362527.

  35. Drake CG. Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68(6):985–6.

    Google Scholar 

  36. Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke. 2001;32(9):2012–20.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to both research and nursing staffs of the department of Anesthesia and Critical Care Medicine of Laënnec University Hospital.

Funding

None.

Author information

Authors and Affiliations

  1. Service d’Anesthésie-Réanimation, Hôpital Laënnec, Centre Hospitalier Universitaire, 44093, Nantes Cedex 1, France

    Karim Lakhal, Antoine Hivert, Marion Fresco, Vincent Robert-Edan, Pierre-André Rodie-Talbere, Xavier Ambrosi, Bertrand Rozec & Julien Cadiet

  2. Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Nantes, Nantes, France

    Pierre-Louis Alexandre & Romain Bourcier

  3. Institut du Thorax, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Nantes, 44093, Nantes, France

    Romain Bourcier & Bertrand Rozec

Authors
  1. Karim Lakhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoine Hivert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre-Louis Alexandre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marion Fresco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincent Robert-Edan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pierre-André Rodie-Talbere
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xavier Ambrosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Romain Bourcier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bertrand Rozec
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Julien Cadiet
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KL contributed to the conception and design of the study, the collection of clinical data, the statistical analysis, and the drafting and revision of the article. AH contributed to the conception and design of the study, the collection of clinical data, and the drafting and revision of the article. PLA contributed to the collection of radiological data and the revision of the article for its important intellectual content. MF contributed to the collection of clinical data and revision of the article for its important intellectual content. VRE contributed to the collection of clinical data and revision of the article for its important intellectual content. PART contributed to the collection of clinical data and revision of the article for its important intellectual content. XA contributed to the collection of clinical data and revision of the article for its important intellectual content. RB contributed to the interpretation of data and revision of the article for its important intellectual content. BR contributed to the interpretation of data and revision of the article for its important intellectual content. JC contributed to the conception and design of the study and the drafting and revision of the article. All authors approve of the final manuscript.

Corresponding author

Correspondence to Karim Lakhal.

Ethics declarations

Conflicts of interest

KL has no conflict of interest in connection with the work submitted. In addition, KL received, during the past 3 years, congress registration fees from Sanofi Aventis (once in 2018), travel fees from Merck Sharp & Dohme (MSD) France (once, in 2017), Gilead Sciences (once, in 2017), pfizer (twice, in 2019 and 2020) and Correvio (twice, in 2020). BR has no conflict of interest in connection with the work submitted. In addition, BR received, during the past 5 years, lecture fees from Fisher&Paykel, Baxter, LFB, Aspen, research grants from Baxter and consulting fees from LFB, Astra Zeneca. None of the other authors has any financial or nonfinancial competing interest in connection with this study.

Ethical Approval/Informed Consent

This research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013). At our institution, intravenous milrinone has been incorporated into routine care several years ago, a dedicated institutional written procedure guiding its use for moderate/severe vasospasms. In patients who were included prospectively (IV milrinone group), consent to use the data for this observational study was obtained from all participants (patients or their next of kin then the patients themselves if they regained capacity) after oral and written reminding of their rights. For patients included retrospectively (historical control cohort), informed consent was waived. Anonymity was respected. This research has been approved by an independent ethical committee (Comité de Protection des Personnes Sud-Ouest & Outre-Mer III, March 2018, N° 2017-A03347-46, amended in march 2019).

Clinical Trials Registration

Ref. NCT 03517670.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOC 988 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lakhal, K., Hivert, A., Alexandre, PL. et al. Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: The MILRISPASM Controlled Before–After Study. Neurocrit Care 35, 669–679 (2021). https://doi.org/10.1007/s12028-021-01331-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-021-01331-z

Keywords

Search

Navigation